Shopping Cart
Remove All
Your shopping cart is currently empty
Linerixibat
Copy Product Info
😃Good
Catalog No. T3978Cas No. 1345982-69-5
Alias Iinerixibat, GSK2330672
Linerixibat (GSK2330672) is a highly effective, nonabsorbable ASBT inhibitor (IC50: 42 ± 3 nM) that can lower glucose in an animal model of type 2 diabetes and demonstrates excellent developability properties.
Linerixibat
Copy Product Info😃Good
Purity: 99.98%
Catalog No. T3978Alias Iinerixibat, GSK2330672Cas No. 1345982-69-5
Linerixibat (GSK2330672) is a highly effective, nonabsorbable ASBT inhibitor (IC50: 42 ± 3 nM) that can lower glucose in an animal model of type 2 diabetes and demonstrates excellent developability properties.
| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 1 mg | $76 | In Stock | In Stock | |
| 2 mg | $119 | In Stock | In Stock | |
| 5 mg | $222 | In Stock | In Stock | |
| 10 mg | $372 | In Stock | In Stock | |
| 25 mg | $629 | In Stock | In Stock | |
| 50 mg | $896 | - | In Stock | |
| 1 mL x 10 mM (in DMSO) | $268 | In Stock | In Stock |
Add to Cart
Add to Quotation
In Stock Estimated shipping dateUSA Warehouse[1-2 days] Global Warehouse[5-7 days]
All TargetMol products are for research purposes only and cannot be used for human consumption. We do not provide products or services to individuals. Please comply with the intended use and do not use TargetMol products for any other purpose.
Batch Information
Select Batch
Purity:99.98%
Color:White
Contact us for more batch information
Product Introduction
Linerixibat AI Summary
Linerixibat exhibits bioactivities related to the inhibition of ASBT (Apical Sodium-dependent Bile Acid Transporter) and displays antidiabetic properties as well as antiviral activity. It shows potent inhibition of ASBT in rat, mouse, and human cell models with varying IC50 values, leading to increased fecal bile acid excretion and high drug recovery in rat feces. In Zucker diabetic fatty rats, it resulted in reduced non-fasted plasma glucose levels and blood HbA1c levels, demonstrating significant antidiabetic activity. The compound also inhibits taurocholate uptake with an IC50 of 43.0 nM and has favorable aqueous solubility and pharmacokinetic profiles in different animal models. Additionally, Linerixibat exhibits antiviral activity by inhibiting SARS-CoV-2 induced cytotoxicity in Caco-2 cells and VERO-6 cells with various inhibition rates and demonstrates SARS-CoV-2 3CL-Pro protease inhibition at 20µM. It also shows inhibitory activity against the human HDAC6 enzyme, suggesting potential as an HDAC6 inhibitor in enzymatic assays..
Note: Summary generated by AI. Data source: ChEMBL 
Bioactivity
Chemical Properties
Storage & Solubility Information
| Description | Linerixibat (GSK2330672) is a highly effective, nonabsorbable ASBT inhibitor (IC50: 42 ± 3 nM) that can lower glucose in an animal model of type 2 diabetes and demonstrates excellent developability properties. |
| Targets&IC50 | ASBT:42 ± 3 nM |
| Synonyms | Iinerixibat, GSK2330672 |
| Molecular Weight | 546.68 |
| Formula | C28H38N2O7S |
| Cas No. | 1345982-69-5 |
| Smiles | CCCC[C@]1(CC)CS(=O)(=O)c2cc(CNC(CC(O)=O)CC(O)=O)c(OC)cc2[C@H](N1)c1ccccc1 |
| Relative Density. | 1.218 g/cm3 (Predicted) |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. | |||||||||||||||||||||||||
| Solubility Information | DMSO: 21.5 mg/mL (39.33 mM), Sonication is recommended. | |||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||
DMSO
| ||||||||||||||||||||||||||
Calculator
In Vivo Formulation Calculator (Clear solution)
Please enter your animal experiment information in the following box and click Calculate to obtain the stock solution preparation method and in vivo formula preparation method:
For example, if the intended dosage is 10 mg/kg for animals weighing 20 g , with a dosing volume of 100 μL per animal, and a total of 10 animals are to be administered, using a formulation of 
10% DMSO+ 40% PEG300+ 5% Tween 80+ 45% Saline/PBS/ddH2O , the resulting working solution concentration would be 2 mg/mL.Stock Solution Preparation:
Dissolve 2 mg of the compound in 100 μL DMSO to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.
Preparation of the In Vivo Formulation:
1) Add 100 μL of the DMSO stock solution to 400 μL PEG300 and mix thoroughly until the solution becomes clear.
2) Add 50 μL Tween 80 and mix well until fully clarified.
3) Add 450 μL Saline,PBS or ddH2O and mix thoroughly until a homogeneous solution is obtained.
This example is provided solely to demonstrate the use of the In Vivo Formulation Calculator and does not constitute a recommended formulation for any specific compound. Please select an appropriate dissolution and formulation strategy based on your experimental model and route of administration.
Dose Conversion
You can also refer to dose conversion for different animals. More Dose Conversion
Tech Support
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc
Keywords
Preview
Related Tags: buy Linerixibat | purchase Linerixibat | Linerixibat cost | order Linerixibat | Linerixibat chemical structure | Linerixibat formula | Linerixibat molecular weight
Generate Quote
Catalog No.: Cas No.:
Add
| Size | Quantity | Unit Price | Amount | Operation |
|---|
Generate Quote
- TOP
Feedback
Hello! How can I help you today? 
Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.